Behavior signals (lifetime)
Dip response
—
—
when a holding falls −10%+
Middle response
—
—
Rally response
—
—
when a holding rises +10%+
Top positions · 26
| Ticker | $ value | % port | YoY | Hold time |
|---|---|---|---|---|
| BMRNBioMarin Pharmaceutical | $72M | 15.4% | — | 0.3 yr |
| VRTXVertex Pharmaceuticals I | $48M | 10.4% | — | 0.3 yr |
| PCVXVaxcyte, Inc. | $37M | 8.0% | — | 0.3 yr |
| NUVLNuvalent, Inc. | $31M | 6.6% | — | 0.3 yr |
| CAPRCapricor Therapeutics, I | $28M | 5.9% | — | 0.3 yr |
| TERNTerns Pharmaceuticals, I | $27M | 5.9% | — | 0.3 yr |
| BCAXBicara Therapeutics Inc. | $25M | 5.4% | — | 0.3 yr |
| ANIPANI Pharmaceuticals, Inc | $24M | 5.3% | — | 0.3 yr |
| RAREUltragenyx Pharmaceutica | $24M | 5.2% | — | 0.3 yr |
| ELVNEnliven Therapeutics, In | $23M | 5.0% | — | 0.3 yr |
| AMLXAmylyx Pharmaceuticals, | $22M | 4.8% | — | 0.3 yr |
| ARGXargenx SE | $19M | 4.1% | — | 0.3 yr |
| FULCFulcrum Therapeutics, In | $14M | 2.9% | — | 0.3 yr |
| VIRVir Biotechnology, Inc. | $11M | 2.3% | — | 0.3 yr |
| NUVBNuvation Bio Inc. | $10M | 2.2% | — | 0.3 yr |
Portfolio composition (YoY)
Industry mix
Biotechnology94.7%$442M
Drug Manufacturers - Specialty & Generic5.3%$24M
Country
US94.6%
NL5.1%
GB0.3%
Top 5: 46.3% · Top 10: 73.1% · Top 25: 99.8%
Winners
| Ticker | Prev $ | PnL | YoY % |
|---|
Losers
| Ticker | Prev $ | PnL | YoY % |
|---|
Top buys this quarter · 15
| BMRN BioMarin Pharmaceutical Inc.new | +$72M |
| VRTX Vertex Pharmaceuticals Incorponew | +$48M |
| PCVX Vaxcyte, Inc.new | +$37M |
| NUVL Nuvalent, Inc.new | +$31M |
| CAPR Capricor Therapeutics, Inc.new | +$28M |
| BCAX Bicara Therapeutics Inc. Commonew | +$25M |
| ANIP ANI Pharmaceuticals, Inc.new | +$24M |
| RARE Ultragenyx Pharmaceutical Inc.new | +$24M |
| ELVN Enliven Therapeutics, Inc.new | +$23M |
| AMLX Amylyx Pharmaceuticals, Inc.new | +$22M |
Top sells this quarter · 0
No sells this quarter
Quarterly history (TTM returns)
| Period | AUM | # Pos | Return (1yr) | SPY (1yr) | Alpha (1yr) | Flow |
|---|---|---|---|---|---|---|
| 2026-03-31 | $466M | 26 | — | — | — | — |